Stephen Clarke — ASN Events

Stephen Clarke

Northern Sydney LHD, NSW, Australia

  • This delegate is presenting an abstract at this event.
Stephen Clarke is a medical oncologist at Royal North Shore Hospital in Sydney and Professor of Medicine at the University of Sydney. He is Director of Cancer Services in Northern Sydney LHD. Having completed his medical oncology training at RNSH, St Leonards, Stephen undertook a PhD at the Institute of Cancer Research/Royal Marsden Cancer Hospital, before returning to Australia in 1994. He worked at RPA and Concord Hospital until 2010 when he returned to RNSH. He has clinical and research interests in thoracic and GI cancers, including Neuroendocrine Cancers and mesothelioma as well as cancer pharmacology and cancer associated inflammation. Stephen’s research has achieved over $25 million in competitive grant funding that has led to over 300 publications, which have been cited over 14000 times. His work has been recognized by the awarding of an OAM in 2011, the Eric Susman prize of the RACP in 2012 and the MOGA Cancer Achievement Award in 2016. Stephen is the Oncology Advisor to the Department of Veteran’s Affairs and is a Member of the Repatriation Pharmaceutical Review Committee. He has been Head of the NSW State Committee of the RACP for 3 years.
Presentations this author is a contributor to:

Symptom burden of Australia and New Zealand (ANZ) patients with Neuroendocrine Tumours (NET)  (#348)

3:00 PM
David L Chan
Posters 2

‘Rethinking REAL-2: Real-life outcomes from an Australian retrospective audit of patients with metastatic oesophago-gastric adenocarcinoma (mOGC)’ (#219)

3:00 PM
Claudia E.A Stretch
Posters1

The impact of physical activity on fatigue and quality of life in lung cancer patients: a randomised controlled trial. (#23)

12:15 PM
Haryana Dhillon
Best of the Best Orals - Clinical research

A retrospective study of dual 18F-fluorodeoxyglucose/68Gallium DOTATATE (FDG/68Ga-DOTATATE) positron emission tomography (PET) grading and its prognostic value in metastatic pancreatic neuroendocrine tumours (PNET) (#349)

3:00 PM
David L Chan
Posters 2

Experience of Australia and New Zealand (ANZ) patients with neuroendocrine tumours (NET) treated at a NET specialist centre: Results of a national survey and the Royal North Shore experience (#350)

3:00 PM
David L Chan
Posters 2

NET Care in Australia; The patient’s perspective of their Neuroendocrine Tumours (NET) and impact of diagnosis (#374)

3:00 PM
John Leyden
Posters 2

The Lymphocyte-to-Monocyte ratio is a superior predictor of OS in comparison to established biomarkers in CRC patients undergoing curative resection. (#19)

11:15 AM
Joseph Chan
Best of the Best Orals - Clinical research

ALK Translocated Non-Small Cell Lung Cancer: Experience from an Australian metropolitan tertiary referral centre. (#367)

3:00 PM
Malinda Itchins
Posters 2

Neuroendocrine tumor (NET) Oceania patient experience: results from the first global NET patient survey - A collaboration between the International Neuroendocrine Cancer Alliance (INCA) and Novartis (#74)

11:30 AM
John Leyden
Best of the Best Orals - Rare Cancers